Gyre Therapeutics (GYRE) Misses Q2 EPS by 6c

Gyre Therapeutics (NASDAQ: GYRE) reported Q2 EPS of ($0.12), $0.06 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $26.49 million.

For earnings history and earnings-related data on Gyre Therapeutics (GYRE) click here.

You May Also Be Interested In

• Activist investors push Seer, Inc. to disclose go-private timeline
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)